<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361500</url>
  </required_header>
  <id_info>
    <org_study_id>COSA-8998</org_study_id>
    <nct_id>NCT04361500</nct_id>
  </id_info>
  <brief_title>Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter</brief_title>
  <acronym>COSA</acronym>
  <official_title>Registry for the Evaluation of Safety and Effectiveness of the Seraph 100 Microbind Affinity Blood Filter in the Therapy of COVID-19 Patients (COSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry study is to investigate the effectiveness and safety of the
      Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2
      worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging
      need for treatment options, especially in critically ill patients. Multiple pharmacological
      and non-pharmacological therapies are being investigated. In 2019, the Seraph® 100 Microbind®
      Affinity Blood Filter (ExThera Medical Corporation, CA, USA) was approved for the removal of
      pathogens in Europe. On April 17th the FDA granted Authorization for Emergency Use in
      patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Overall Survival after Seraph 100 therapy session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days</time_frame>
    <description>Time spend in the ICU after Seraph 100 therapy session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Time spend in the hospital after Seraph 100 therapy session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ventilator therapy</measure>
    <time_frame>30 days</time_frame>
    <description>Time spend on ventilator after Seraph 100 therapy session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Report of any Seraph 100 therapy related adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients with Seraph 100 therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seraph 100</intervention_name>
    <description>Seraph 100 therapy during a COVID-19 infection</description>
    <arm_group_label>COVID-19 patients with Seraph 100 therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with prooven COVID-19 infection with confirmed or imminent respiratory failure and
        Treatment with the Seraph® 100 Microbind® Affinity Blood Filter.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 infection

          -  Treatment with the Seraph® 100 Microbind® Affinity Blood Filter

          -  Voluntary consent to participate in Registry

        Exclusion Criteria:

        - none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julius J Schmidt, Dr</last_name>
    <phone>+495115326319</phone>
    <email>schmidt.julius@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan T Kielstein, Prof</last_name>
    <phone>+495315952380</phone>
    <email>kielstein@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Teaching Hospital Brunswick</name>
      <address>
        <city>Brunswick</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan T Kielstein, Prof</last_name>
      <email>kielstein@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julius J Schmidt, Dr</last_name>
      <email>schmidt.julius@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Julius J Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard MW Schmidt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

